Drugs · Entity Annotation Prototype (beta)

3articles mentioning drugs

7drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: IO ×

IO

This drug is selected. Its supporting articles are shown below.

IO3

Articles mentioning IO

3 articles · page 1 of 1

444 Impact of homologous recombination deficiency on response to chemoimmunotherapy in biliary tract cancer

jitc · abstract · 2025-11-04 · 4 matching annotations

94.0%

IO CIO CT BTC Institutional Review Boards CIO

… the addition of IO to CT in patients with BTC. The addition of IO to CT did not significantly improve survival outcomes over CT a…

721 Enhancing retention through reinforcement: the value of a curriculum of educational programs about resectable cutaneous squamous cell carcinoma (CSCC)

jitc · abstract · 2025-11-04 · 2 matching annotations

80.9%

IO neoadjuvant IO non-melanoma skin cancer immunotherapy resectable CSCC NMSC

…Background The use of immunotherapy (IO) has dramatically changed the treatment landscape for non-melan…

689 The mTORC1/2 dual inhibitor AZD2014 enhances inotuzumab ozogamicin-induced apoptosis in B-cell non-hodgkin lymphoma cells via lysosomal function activation

jitc · abstract · 2025-11-04 · 1 matching annotations

76.1%

gemtuzumab ozogamicin Inotuzumab ozogamicin AZD2014 gemtuzumab ozogamicin-induced IO Kobe University B-cell non-Hodgkin lymphoma B-cell acute lymphoblastic leukemia B-cell NHL diffuse large B-cell lymphoma (DLBCL)

…t al. An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function. Leuk Res. 2018 Nov;74:68–7…